Browsing by Author Qin, A

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 5 of 5
TitleAuthor(s)Issue DateViews
 
MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
Proceeding/Conference:Clinical Lymphoma Myeloma and Leukemia
Mesa, RKomatsu, NSingh, GHHJin, JLee, SEHou, HASato, TQin, AUrbanski, RShih, WOleh, ZCraig, CVerstovsek, S
2022
 
Novel Strategy for Constructing High Efficiency OLED Emitters with Excited State Quinone‐Conformation Induced Planarization Process
Journal:Advanced Optical Materials
NcWu, HPan, YZeng, JDu, LLuo, WZhang, HXue, KChen, PPhillips, DLWang, ZQin, ATang, B
2019
16
 
Structural modification on tetraphenylpyrazine: from polarity enhanced emission to polarity quenching emission and its intramolecular charge transfer mechanism
Journal:Journal of Materials Chemistry C
Wu, HDu, LLuo, JWang, ZPhillips, DLQin, ATang, BZ
2022
5
 
Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia
Proceeding/Conference:Blood
Mesa, RAKomatsu, NSingh, GHHJin, JLee, SEHou, HASato, TQin, AUrbanski, RShih, WZagrijtschuk, CZimmerman, CVerstovsek, S
2021
27
 
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia
Journal:Future Oncology
Verstovsek, SKomatsu, NSingh, GHHJin, JLee, SEHou, HASato, TQin, AUrbanski, RShih, WZagrijtschuk, OZimmerman, CMesa, RA
2022
1
Showing results 1 to 5 of 5